Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT02834390 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Quizartinib
DRUG: Cytarabine
DRUG: Idarubicin
DRUG: Daunorubicin

Sponsor

Daiichi Sankyo Co., Ltd.